Key result
In the general population, MR-proANP and MR-proADM were strongly associated with noninvasive measures of conduit artery and peripheral arterial performance.
Why the study?
Are circulating biomarkers of cardiovascular function associated with noninvasive measures of vascular function in the general population?
Cross-Sectional (n=5,000)
Are circulating biomarkers of cardiovascular function associated with noninvasive measures of vascular function in the general population?
MR-proADM and MR-proANP are circulating biomarkers strongly related to noninvasive measures of conduit artery and peripheral arterial performance in the general population.
Answers are grounded in this paper and cite their sources.
Associations warrant no practice change yet; leaves open prospective validation of these biomarkers for vascular risk stratification.
Vascular reactivity is reflected by blood biomarkers and noninvasive vascular function measurement. The relation of biomarkers to flow-mediated dilation and peripheral arterial tonometry in the general population is little understood. In 5000 individuals (mean age, 56±11 years; age range, 35-74 years; 49% women) of the population-based Gutenberg Health Study we simultaneously assessed 6 biomarkers of cardiovascular function (midregional proadrenomedullin [MR-proADM], midregional pro atrial natriuretic peptide [MR-proANP], N-terminal pro B-type natriuretic peptide, copeptin, C-terminal proendothelin 1, and neopterin) in relation to flow-mediated dilation and peripheral arterial tonometry. Strongest partial correlations (adjusted for age and sex) were observed for baseline pulse amplitude with MR-proADM (r=0.13) and MR-proANP (r=-0.13); hyperemic response variables showed the highest correlation for MR-proADM and peripheral arterial tonometry ratio (r=-0.14). In multivariable linear regression models, strongest associations with baseline vascular function were observed for MR-proANP with baseline pulse amplitude (β per SD increase [99.17%], -0.080 [-0.115 to -0.044]; P<0.0001 after Bonferroni correction for multiple testing) and MR-proADM (-0.044 [-0.070 to -0.017]; P<0.0001), as well as MR-proANP (-0.033 [-0.057 to -0.009]; P=0.0017) and N-terminal pro B-type natriuretic peptide (-0.027 [-0.051 to -0.003]; P=0.015) with brachial artery diameter. For hyperemic response variables, highest associations were seen for peripheral arterial tonometry ratio with MR-proADM (-0.022 [-0.043 to -0.004]; P=0.043), MR-proANP (0.016 [-0.0034 to 0.035]; P=0.18), and C-terminal proendothelin 1 (-0.025 [-0.043 to -0.008]; P=0.00094]. In our large, population-based study, we identified MR-proADM and MR-proANP as circulating biomarkers of vascular function most strongly related to noninvasive measures of conduit artery and peripheral arterial performance. Whether determination of blood biomarkers helps to better understand vascular pathology and may provide prognostic information needs to be investigated in future studies.
No takes yet. Share an insight, caveat, or question.
Schnabel et al. (2012) conducted a cross-sectional in General population (n=5,000). Circulating endothelial biomarkers (MR-proADM, MR-proANP, NT-proBNP, copeptin, CT-proET-1, neopterin) was evaluated on Baseline pulse amplitude (β -0.080, 95% CI -0.115 to -0.044, p=<0.0001). In the general population, MR-proANP and MR-proADM were strongly associated with noninvasive measures of conduit artery and peripheral arterial performance.
Synapse has enriched 10 related papers. Consider them for comparative context: